GreenRoc Accelerates their World Class Project to Production as Early as 2028. Watch the full video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksARIX.L Regulatory News (ARIX)

  • There is currently no data for ARIX

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Clinical portfolio update

11 Jun 2021 13:05

Arix Bioscience PLC (ARIX) Clinical portfolio update 11-Jun-2021 / 13:05 GMT/BST Dissemination of a Regulatory Announcement, transmitted by EQS Group. The issuer is solely responsible for the content of this announcement.


 

Arix Bioscience plc

 

Clinical portfolio update

 

 

LONDON, 11 June 2021: Arix Bioscience plc ("Arix", LSE:ARIX), a global venture capital company focused on investing in and building breakthrough biotech companies, today notes clinical progress in its portfolio companies, Harpoon Therapeutics (Nasdaq: HARP, "Harpoon"), Imara Inc. (Nasdaq: IMRA, "Imara"), Autolus Therapeutics plc (Nasdaq: AUTL, "Autolus") and LogicBio Therapeutics, Inc. (Nasdaq: LOGC, "LogicBio"), in June.

 

Imara (5.7% ownership stake)

 

Imara announced the presentation of data from the Phase 2a clinical trial and its open label extension (OLE) trial of IMR-687 in adults with sickle cell disease at the European Hematology Association (EHA) Annual Congress, being held virtually June 9-17, 2021.

Data indicate that that IMR-687 has a well-tolerated safety profile as a monotherapy and in combination with hydroxyurea in both studies, with a lower annualised rate of vaso-occlusive crises.

 

Imara will host a live webcast today at 8:00 a.m. ET. The live webcast and presentation slides will be available under "Events and Presentations" in the Investors section of the company's website. A replay of the webcast will be archived on the Imara website following the presentation.

 

The full announcement from Imara can be accessed here: https://imaratx.gcs-web.com/news-releases/news-release-details/imara-presents-clinical-data-imr-687-sickle-cell-disease

 

Harpoon (6.7% ownership stake)

 

Harpoon provided a pipeline update on its four clinical stage programmes, including updating the interim data presented at ASCO from the ongoing dose escalation portion of the Phase 1/2a trial for HPN424 in patients with metastatic castration resistant prostate cancer. Harpoon noted that all four clinical programmes demonstrate half-life extension, target engagement and T cell activation. The company also notes that three TriTAC clinical programmes (HPN424, HPN536 and HPN328) have shown tumour size reductions or stable disease, and meaningful treatment duration.

 

The full announcement from Harpoon can be accessed here: https://ir.harpoontx.com/news-releases/news-release-details/harpoon-therapeutics-provides-progress-update-tritacr-clinical

 

Autolus (0.8% ownership stake)

 

Autolus announced a poster presentation related to AUTO1 (obecabtagene autoleucel, obe-cel) in relapsed / refractory (r/r) indolent B cell lymphomas (IBCL) and included an update of duration of response in r/r adult Acute Lymphoblastic Leukemia (ALL) patients at the EHA Virtual Congress 2021.

 

Autolus notes that obe-cel achieves 100% complete remission rate in a cohort of indolent B Cell Non-Hodgkin lymphoma patients with excellent CAR T engraftment, expansion, and persistence. Autolus also notes that durability of response in ALL patients continues to support potential for transformational therapy in adult ALL.

 

Management will host a webcast today at 8:30 am ET/1:30 pm BST to discuss the data presented at EHA. To listen to the webcast and view the accompanying slide presentation, please go to the events section of Autolus' website.

 

The full announcement from Autolus can be accessed here: https://autolus.gcs-web.com/news-releases/news-release-details/autolus-therapeutics-presents-new-data-obe-cel-rr-indolent-b

 

LogicBio (9.3% ownership stake)

 

LogicBio announced that the first patient has been dosed with LB-001, the company's investigational single-administration gene editing therapy based on its proprietary GeneRide(TM) platform, in the SUNRISE Phase 1/2 clinical trial in paediatric patients with methylmalonic acidemia.

 

LogicBio remains on track to announce an update on enrollment, dose escalation and age de-escalation in late 2021 and interim data by year-end 2021.

 

The full announcement from LogicBio can be accessed here: https://investor.logicbio.com/news-releases/news-release-details/logicbio-therapeutics-announces-first-patient-dosed

 

[ENDS]

 

For more information on Arix, please contact:

 

Arix Bioscience plc

Charlotte Parry, Head of Investor Relations

+44 (0)20 7290 1072

charlotte@arixbioscience.com

 

 

Optimum Strategic Communications

Mary Clark, Supriya Mathur, Shabnam Bashir

+44 (0)20 3922 1906

optimum.arix@optimumcomms.com

 

 

About Arix Bioscience plc

Arix Bioscience plc is a global venture capital company focused on investing in and building breakthrough biotech companies around cutting-edge advances in life sciences.

We collaborate with exceptional entrepreneurs and provide the capital, expertise and global networks to help accelerate their ideas into important new treatments for patients. As a listed company, we are able to bring this exciting growth phase of our industry to a broader range of investors. www.arixbioscience.com

 

 


ISIN:GB00BD045071
Category Code:MSCH
TIDM:ARIX
LEI Code:213800OVT3AHQCXNIX43
OAM Categories: 3.1. Additional regulated information required to be disclosed under the laws of a Member State
Sequence No.:110863
EQS News ID:1207152
 
End of AnnouncementEQS News Service

UK Regulatory announcement transmitted by DGAP - a service of EQS Group AG. The issuer is solely responsible for the content of this announcement.

Date   Source Headline
3rd Dec 20187:00 amPRNAutolus announces update on AUTO4 and AUTO5 programmes
15th Nov 20187:00 amPRNPositive Phase 1 clinical trial results
12th Nov 20187:00 amPRNArix invests in $70m Harpoon Series C investment round
2nd Nov 201811:33 amPRNAutolus Therapeutics to Present New Data at the ASH
30th Oct 20182:11 pmPRNAura Biosciences reports positive Phase 1b/2 data
24th Oct 20187:00 amPRNLogicBio announces closing of initial public offering
19th Oct 20187:00 amPRNLogicBio prices Nasdaq IPO
10th Oct 20187:00 amPRNUpdate on LogicBio proposed IPO in the United States
1st Oct 20187:00 amPRNCo-leads $58 million Series A for VelosBio
26th Sep 20187:00 amPRNLogicBio files registration for proposed IPO in the US
18th Sep 20182:00 pmPRNUpdate on Iterum Therapeutics Phase 3 trials
12th Sep 20184:30 pmPRNAnnounces Board Changes
10th Sep 20184:24 pmPRNHolding(s) in Company
4th Sep 20187:00 amPRNChanges announced to executive team
17th Aug 20181:01 pmPRNHoldings in Company and Lock-in Agreement
10th Aug 20187:01 amPRNPositive clinical progression in Group Businesses
10th Aug 20187:00 amPRNArtios completes £65m Series B investment round
6th Aug 20187:00 amPRNArix Bioscience announces first VIPE investment
30th Jul 20187:00 amPRNInterim Results for the Six Months Ended 30 June 2018
25th Jul 20184:41 pmPRNNotice of Results
2nd Jul 20181:16 pmPRNTotal Voting Rights
26th Jun 20185:30 pmPRNAutolus annouces closing of IPO
22nd Jun 20187:07 amPRNAutolus Announces Pricing of Initial Public Offering
21st Jun 201810:22 amPRNIssue of Shares, Total Voting Rights & PDMR Notification
11th Jun 20184:23 pmPRNDirector/PDMR Shareholding
8th Jun 201811:36 amPRNUpdate on Autolus proposed NASDAQ IPO
31st May 20182:00 pmPRNLord John Hutton steps down from Board of Directors
30th May 20184:13 pmPRNIterum Therapeutics plc Closes Initial Public Offering
25th May 20187:19 amPRNIterum Therapeutics plc Prices Initial Public Offering
17th May 201812:29 pmRNSResult of AGM
17th May 20187:00 amRNSUpdate on Iterum proposed NASDAQ IPO
8th May 20187:00 amRNSAutolus Files for Proposed US IPO
2nd May 201810:10 amRNSArix notes Iterum?s proposed US IPO
23rd Apr 20187:00 amRNSAnnual Results 2017
16th Apr 20187:25 amRNSNotice of Annual Results
5th Apr 20187:00 amRNSArix to present at HC Wainwright on 10 April
4th Apr 20189:01 amRNSHolding(s) in Company
4th Apr 20189:00 amRNSTotal Voting Rights
26th Mar 20181:40 pmRNSHolding(s) in Company
26th Mar 201812:31 pmRNSArix notes positive Ph2b COPD data from Verona
23rd Mar 20189:00 amRNSHolding(s) in Company
22nd Mar 201811:51 amRNSHolding(s) in Company
21st Mar 201812:46 pmRNSHoldings in Company
21st Mar 201811:40 amRNSDirector/PDMR Shareholding
21st Mar 201811:39 amRNSHolding(s) in Company
16th Mar 201811:45 amRNSResults of General Meeting
16th Mar 20187:00 amRNSResults of Capital Raising
6th Mar 20187:00 amRNSArix notes Autolus's potential US IPO
28th Feb 201811:29 amRNSPublication of a Prospectus
28th Feb 20187:00 amRNSProposed Firm Placing, Placing and Offer

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.